New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

CAMP4 Therapeutics Corporation (CAMP) vs Prelude Therapeutics Incorporated (PRLD)

CAMP4 Therapeutics Corporation and Prelude Therapeutics Incorporated are both Biotechnology companies. CAMP4 Therapeutics Corporation and Prelude Therapeutics Incorporated are of similar size ($260.5M and $251.0M). Prelude Therapeutics Incorporated has the higher net margin (−247.1% vs −2,276.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Prelude Therapeutics Incorporated leads on 10 and CAMP4 Therapeutics Corporation on 2.

Valuation

Metric CAMP PRLD Biotechnology median
P/E n/m n/m 8.49
P/S 56.24 15.44 8.56
P/B 2.79 2.68 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales 32.70 8.95 8.00
Earnings yield (53.22%) (18.32%) (35.81%)
Free cash flow yield (8.81%) (8.40%) (25.41%)

Profitability

Metric CAMP PRLD Biotechnology median
Gross margin 100.00% 100.00% 70.18%
Operating margin (1,001.05%) (283.92%) 0.00%
Net margin (2,276.33%) (247.12%) 0.00%
Free cash flow margin — (129.68%) 0.00%
Return on equity (146.12%) (58.36%) (51.58%)
Return on assets (109.89%) (39.45%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CAMP PRLD Biotechnology median
Revenue growth (TTM) 52.00% — 7.20%
EPS growth (last fiscal year) 76.00% 23.21% 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric CAMP PRLD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.42 4.20 4.79
Net debt to EBITDA 2.18 1.00 1.01

Dividend

Metric CAMP PRLD Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CAMP PRLD Biotechnology median
Market cap 251.01m 260.48m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack